286 related articles for article (PubMed ID: 27439899)
21. RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C; Yang R
J BUON; 2019; 24(2):715-719. PubMed ID: 31128028
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma.
Zhao X; Guo F; Li Z; Jiang P; Deng X; Tian F; Li X; Wang S
Oncol Rep; 2016 Jul; 36(1):419-27. PubMed ID: 27177355
[TBL] [Abstract][Full Text] [Related]
23. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer.
Han S; Wang Y; Shi X; Zong L; Liu L; Zhang J; Qian Q; Jin J; Ma Y; Cui B; Yang X; Kong B; Zhang Y
Exp Cell Res; 2018 Oct; 371(1):222-230. PubMed ID: 30099052
[TBL] [Abstract][Full Text] [Related]
24. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of B7-H4 in tumor infiltrated dendritic cells.
Cheng C; Qu QX; Shen Y; Lv YT; Zhu YB; Zhang XG; Huang JA
J Immunoassay Immunochem; 2011; 32(4):353-64. PubMed ID: 21728826
[TBL] [Abstract][Full Text] [Related]
26. Could B7-H4 serve as a target to activate anti-cancer immunity?
Wang L; Heng X; Lu Y; Cai Z; Yi Q; Che F
Int Immunopharmacol; 2016 Sep; 38():97-103. PubMed ID: 27258187
[TBL] [Abstract][Full Text] [Related]
27. [Preparation of anti-B7-H4 monoclonal antibody to investigate B7-H4 expression in pancreatic cancer].
Hong B; Qian Y; Yao HP
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):511-6. PubMed ID: 24167131
[TBL] [Abstract][Full Text] [Related]
28. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
29. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
30. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
[TBL] [Abstract][Full Text] [Related]
31. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
32. Endogenous expression of B7-H4 improves long-term murine islet allograft survival.
Wang X; Hao J; Metzger DL; Mui A; Lee IF; Akhoundsadegh N; Ao Z; Chen L; Ou D; Verchere CB; Warnock GL
Transplantation; 2013 Jan; 95(1):94-9. PubMed ID: 23192157
[TBL] [Abstract][Full Text] [Related]
33. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
Miyatake T; Tringler B; Liu W; Liu SH; Papkoff J; Enomoto T; Torkko KC; Dehn DL; Swisher A; Shroyer KR
Gynecol Oncol; 2007 Jul; 106(1):119-27. PubMed ID: 17509674
[TBL] [Abstract][Full Text] [Related]
34. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity.
Sica GL; Choi IH; Zhu G; Tamada K; Wang SD; Tamura H; Chapoval AI; Flies DB; Bajorath J; Chen L
Immunity; 2003 Jun; 18(6):849-61. PubMed ID: 12818165
[TBL] [Abstract][Full Text] [Related]
35. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family.
Choi IH; Zhu G; Sica GL; Strome SE; Cheville JC; Lau JS; Zhu Y; Flies DB; Tamada K; Chen L
J Immunol; 2003 Nov; 171(9):4650-4. PubMed ID: 14568939
[TBL] [Abstract][Full Text] [Related]
36. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
37. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity.
Xue Q; Luan XY; Gu YZ; Wu HY; Zhang GB; Yu GH; Zhu HT; Wang M; Dong W; Geng YJ; Zhang XG
Stem Cells Dev; 2010 Jan; 19(1):27-38. PubMed ID: 19788399
[TBL] [Abstract][Full Text] [Related]
38. [B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors].
Zeng S; Song H; Chen Y; Xie W; Zhang L
Mol Biol (Mosk); 2016; 50(6):1007-1013. PubMed ID: 28064317
[TBL] [Abstract][Full Text] [Related]
39. Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines.
Sun SQ; Jiang CG; Lin Y; Jin YL; Huang PL
J Int Med Res; 2012; 40(2):497-506. PubMed ID: 22613410
[TBL] [Abstract][Full Text] [Related]
40. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
